View on Pubmed.gov 11309497 | View on doi.org 10.1073/pnas.09...
A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport.
- Metabolic Diseases Drug Discovery and Nuclear Receptor Discovery Research, GlaxoSmithKline, Research Triangle Park, NC 27709, USA.
Abstract
The peroxisome proliferator-activated receptors (PPARs) are dietary lipid sensors that regulate fatty acid and carbohydrate metabolism. The hypolipidemic effects of the fibrate drugs and the antidiabetic effects of the glitazone drugs in humans are due to activation of the alpha (NR1C1) and gamma (NR1C3) subtypes, respectively. By contrast, the therapeutic potential of the delta (NR1C2) subtype is unknown, due in part to the lack of selective ligands. We have used combinatorial chemistry and structure-based drug design to develop a potent and subtype-selective PPARdelta agonist, GW501516. In macrophages, fibroblasts, and intestinal cells, GW501516 increases expression of the reverse cholesterol transporter ATP-binding cassette A1 and induces apolipoprotein A1-specific cholesterol efflux. When dosed to insulin-resistant middle-aged obese rhesus monkeys, GW501516 causes a dramatic dose-dependent rise in serum high density lipoprotein cholesterol while lowering the levels of small-dense low density lipoprotein, fasting triglycerides, and fasting insulin. Our results suggest that PPARdelta agonists may be effective drugs to increase reverse cholesterol transport and decrease cardiovascular disease associated with the metabolic syndrome X.
References
Curr Opin Lipidol. 2000 Dec;11(6):597-602
Mol Cell. 2001 Jan;7(1):161-71
J Natl Cancer Inst. 1976 Apr;56(4):843-9
Diabetologia. 1986 Oct;29(10):713-9
Cited by 1054 citations (total)
Journal Article
Peroxisome proliferator-activated receptors in the modulation of the immune/inflammatory response in atherosclerosis.
Electronic publication date September 5, 2008
Ana Z Fernandez
Inflammation has been recognized as an important hallmark of atherosclerosis. The pharmacological activation of PPAR-gamma by the thiazolidinediones in diabetes,...
Journal Article Review
Atherosclerosis and cardiovascular risk reduction with PPAR agonists.
Electronic publication date February 7, 2008
Johanna Kuusisto [...] Markku Laakso et al.
Peroxisome proliferator-activated receptors (PPARs) are transcriptional factors belonging to the nuclear receptor superfamily. Three isoforms, PPARalpha, PPARgamma, and PPARdelta, which...
Conflict of interest statement
MeSH
- •
- •
- •
- •
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
Substances
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •